Press Releases

Date Title View
Toggle Summary Second Sight to Present at the 27th Annual ROTH Conference on March 9, 2015
SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today announced that Dr.
View HTML
Toggle Summary Second Sight Receives Highest Priority Reimbursement for Argus II in Germany
SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (Nasdaq:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today announced that InEK 1 , the German national system
View HTML
Toggle Summary Health Canada Approves Second Sight's Argus II Retinal Prosthesis System for Treatment of Outer Retinal Degeneration
Argus II is the First Approved ‘Bionic Eye' in Canada for the Treatment of Blindness due to Outer Retinal Degeneration SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (Nasdaq: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable
View HTML
Toggle Summary Second Sight's Argus® II Retinal Prosthetic Implant to be Sold in Turkey
SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (Nasdaq:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to restore some functional vision to blind patients, today announced that it has entered into an exclusive
View HTML
Toggle Summary Second Sight Announces Underwriter Exercises Over-Allotment Option
SYLMAR, Calif. , Nov. 24, 2014 (GLOBE NEWSWIRE) -- Second Sight Medical Products, Inc. (Nasdaq:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to restore some functional vision to blind patients, today announced that the underwriter
View HTML
Toggle Summary Second Sight Announces Pricing of Initial Public Offering
SYLMAR, Calif., Nov. 19, 2014 (GLOBE NEWSWIRE) -- Second Sight Medical Products, Inc. ("Second Sight") today announced the pricing of its initial public offering of 3,500,000 shares of common stock, at a price of $9.00 per share. Second Sight develops, manufactures and markets implantable visual
View HTML
Toggle Summary Second Sight Argus® II Retinal Prosthesis System to be trialled in blind dry AMD patients for the first time
Five blind patients with AMD will receive groundbreaking Argus II 'bionic eye' treatment at Manchester Royal Eye Hospital
View HTML
Toggle Summary Second Sight Argus® II Retinal Prosthesis System wins financial support agreement in France View HTML
Toggle Summary Second Sight Argus® II Retinal Prosthesis System is granted innovation funding by the French Ministry of Social Affairs and Health View HTML
Toggle Summary Second Sight Announces First Commercial Implants of the Argus® II Retinal Prosthesis System In the United States
Argus® II is the first approved bionic eye in the U.S. for the treatment of blindness due to Retinitis Pigmentosa
View HTML